Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated Sarcomas

Recruiting

Phase 3

Immunotherapy & ChemotherapyMeasuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated Sarcomas

Sponsor:

National Cancer Institute (NCI)

Code:

NCT06422806

Conditions

Metastatic Undifferentiated Pleomorphic Sarcoma

Stage III Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8

Stage IV Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8

Unresectable Undifferentiated Pleomorphic Sarcoma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Biospecimen Collection

Diagnostic Imaging Testing

Doxorubicin

Echocardiography Test

Multigated Acquisition Scan

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-08-27. This information was provided to ClinicalTrials.gov by National Cancer Institute (NCI) on 2025-08-13.